HomeProducts › Diabetes › Mounjaro 5mg KwikPen

Mounjaro 5mg KwikPen

Salt Composition: TIRZEPATIDE

₹13499.00₹16406.25

Inclusive of all taxes

Categories: Diabetes

Conditions: Diabetes Mellitus

Product Introduction

Mounjaro is a GLP-1 receptor agonist used when lifestyle modifications including diet and exercise do not adequately manage blood glucose levels. The Mounjaro 5 mg KwikPen is a prefilled, multi-dose pen designed for convenient self-administration at home. Each pen contains four fixed doses of the specified strength—for example, a 5 mg pen holds a total of 20 mg of tirzepatide (4 doses × 5 mg), 0.6 ml each. Patients inject one dose per week, so each pen is designed to last for one month. Patients with questions about the number of doses in Mounjaro 5 mg KwikPen or about using a different dose from the pen should understand that it is important to follow the prescribed dosage exactly and not adjust doses manually, as the pen delivers fixed, pre-measured doses to ensure safe and effective blood-sugar control. This GLP-1 medication is specifically indicated for type 2 diabetes and should not be used for type 1 diabetes or diabetic ketoacidosis. Patients with a history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2) must avoid this treatment. Mounjaro should be used only under the supervision of a qualified healthcare provider.

Uses

Mounjaro 5mg KwikPen is approved for: Improves blood sugar control in adults with type 2 diabetes mellitus through the action of a GLP-1 receptor agonist. Used in combination with diet and exercise for better glycaemic management. This GLP-1 medication may be used alone or together with other diabetes medicines, as prescribed by a healthcare provider.

How it works

Tirzepatide acts by mimicking two key gut hormones GIP and GLP-1, which play critical roles in glucose regulation: Stimulating insulin secretion in response to elevated blood sugar levels. Reducing glucose production by the liver. Slowing gastric emptying, which prolongs feelings of fullness and may reduce food intake. Together, these actions help maintain more stable blood glucose levels throughout the day, contributing to improved glycemic control.

Side Effects

Common Side Effects: Nausea Vomiting Diarrhea Constipation Decreased appetite Injection site reactions (redness, itching) Serious Side Effects: Pancreatitis (severe abdominal pain) Gallbladder issues (pain in the upper right abdomen) Allergic reactions (rash, swelling, difficulty breathing) Kidney problems due to dehydration from vomiting or diarrhea Thyroid tumors (rare but serious; watch for neck swelling or hoarseness)

References

  1. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  2. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and
  3. https://www.lilly.com/en-CA/resources/faq/mounjaro-kwikpen/strengths-and-doses
  4. https://pi.lilly.com/ca/mounjaro-ca-ifu-kp.pdf

Safety Advice

Pregnancy: Unsafe Mounjaro 5mg KwikPen is not recommended during pregnancy due to limited human data. Animal studies show potential harm.

Lungs: Safe Mounjaro 5mg KwikPen is not known to affect the lungs directly, but if you have respiratory conditions, inform your doctor before use.

Breastfeeding: Consult Your Doctor It is unknown whether tirzepatide passes into breast milk. Mounjaro 5mg KwikPen should only be used if clearly needed.

Disclaimer

The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.

Written By: Muskan Patel, M.Pharm

Reviewed By: Dr. Vishwa Patel, MBBS